Kornimate/medical-research-clean huggingface dataset:
assessment of schizophrenia patients' clinical study experiences

Conditions: Schizophrenia

Summary: the study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. the primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. the data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * considered reliable, able to understand, and willing to perform all study procedures * signed written informed consent exclusion criteria: * currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug * is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * any serious and/or unstable pre-existing medical disorders

Keywords: schizophrenia
study of the pronostic impact of immunohistochemical, histological and radiological factors in patients with primary central nervous system lymphoma.

Conditions: Rare Disease With Poor Outcome

Summary: primary central nervous system lymphoma (pcnsl) have a specific mutational profile in comparison to systemic diffuse large cells lymphoma (dlbcls) that can be related to the expression of immunohistochemical markers as cyclon, npm1, cd30, and p53 which could be predictive factor for prognosis and/or chemotherapy response. the main objective of this study is to identify new prognostic factors and new potential therapeutic targets. the secondary objectives are to correlate the histological, the radiological and the clinical's informations of these patients.


Eligibility criteria:
inclusion criteria: * pcnsl diagnosed between january 2011 and december 2019, without regard to the clinical outcome. * age \> 18 exclusion criteria: * systemic dlbcl
compression feedback for patients with in-hospital cardiac arrest

Conditions: Cardiopulmonary Arrest; Cardiopulmonary Resuscitation

Summary: a prospective, randomized, controlled, parallel study was conducted in patients undergoing resuscitation with chest compression for in-hospital cardiac arrest (ihca) in the mixed medical-surgical icu's of 8 academic tertiary care hospitals in iran. patients randomized into 2 groups: 1) standard chest compression, 2) chest compression with real-time audio-visual feedback using the cardio first angel™ (cfa; inotech, nubberg, germany) device. the primary outcome was sustained return of spontaneous circulation (rosc). secondary outcomes were survival to icu and hospital discharge, incidence of sternum and rib fractures.

a prospective, randomized, controlled, parallel study was conducted in patients undergoing resuscitation with chest compression for in-hospital cardiac arrest (ihca) in the mixed medical-surgical icu's of 8 academic tertiary care hospitals in iran. patients randomized into 2 groups: 1) standard chest compression, 2) chest compression with real-time audio-visual feedback using the cardio first angel™ (inotech, nubberg, germany) device. randomization accomplished using random allocation software© (ras; informer technologies, inc., madrid, spain). crossover was not allowed. the patient and data analyzer were blinded. the clinical provider was not blinded. the primary outcome was sustained return of spontaneous circulation (rosc). secondary outcomes were survival to icu and hospital discharge, incidence of sternum and rib fractures.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * admitted to the intensive care unit (icu) * full-code status * informed consent was obtained from the patient, legal guardian, or healthcare surrogate upon icu admission (prior to cardiac arrest event) exclusion criteria: * patients with any limitation of code status including but not limited to "no code" or"do not resuscitate" (dnr) and"do not intubate" (dni), were excluded from study participation

Keywords: cardio first angle cpr cardiopulmonary arrest clinical trial
patterns after administration of mcfas in psoriasis and psoriatic arthritis

Conditions: Psoriasis; Psoriatic Arthritis

Summary: this is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the treg counts and pasi scores with pevco given at 1000 mg four times daily in patients with pso (subjects may or may not have psa) , who have active disease and are not currently receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy subjects. the patients and healthy controls will receive placebo or pevco for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for pevco). no topical or systemic medications will be used during this period.


Eligibility criteria:
inclusion criteria: * have an active \[psoriatric plaque \>2cm exclusion criteria: * history of sensitivity to study compound or any of their excipients * previous intolerance to pevco or related compounds * current (within 3 months of screening) treatment with dmards * current (within 3 months of screening) treatment with biologic therapies (including but limited to anti-tnf,anti-il-17, anti-il-12/23) * current antibiotic treatment (within 3 months of screening) * current consumption of probiotics (within 3 months of screening) * severe hepatic impairment (eg, ac-sites and/or clinical signs of coagulopathy) * renal failure (egfr ,30 or require dialysis) by history * history of other autoimmune or inflammatory skin disease * current immunodeficiency state (cancer, hiv, others) * current immunodeficiency state (cancer, hiv, other) * concern for inability of the patient to comply with study procedure, and or follow up (alcohol or drug abuse)
promoting weight loss through diet and exercise in overweight women with breast cancer

Conditions: Breast Cancer

Summary: the investigators aim to evaluate the effect of a 6-month intervention (counseling) focused on weight loss in a group of overweight or obese women previously treated for early breast cancer. intervention is designed to improve adherence to a healthy diet or/and to increase physical activity and decrease sedentary time, taking advantage of a pedometer-like device.

the informa project is designed as a mono-institutional randomized controlled 4-arm parallel-group trial. potential study participants will be recruited among all overweight or obese breast cancer patients previously treated at the european institute of oncology (ieo). potential study participants will be recruited after breast cancer treatments (surgery, chemotherapy and and/or radiation) will be completed. study participants will be randomized to one of the 4 arms: di - dietary intervention; pai - physical activity intervention; padi - physical activity and dietary intervention; lii - less intensive intervention. enrolled patients will receive a 6-month intervention and will be followed until the end of the study period with two additional follow-up visits at 12- and 24-month. the main aim of the study is to evaluate the impact of the intervention programme on body weight change in overweight or obese breast cancer patients.

Eligibility criteria:
inclusion criteria: * diagnosed with a first invasive non-metastatic breast carcinoma histologically confirmed, * bmi \> 25, * within 6-month/one year of completion of main cancer treatment, * being able to participate in the intervention, * agree to wear the wrist-based activity monitor during the study period, * agree to be randomized to either group, * written informed consent. exclusion criteria: * severe medical condition or advanced age impeding the patient to adhere at the planned study follow-up period, * contraindications to exercise due to history of heart condition, stroke, chest pain during activity or rest, severe hypertension * orthopaedic disability that would prevent optimal participation in the physical activities prescribed, * patient is unable to find transportation to the study location over the study period, - or * plans to move away from lombardy or to be out of town for more than 3 weeks during the study period.

Keywords: breast cancer obesity weight control exercise and physical fitness
e-mobile tablet for people with chronic conditions

Conditions: Fibromyalgia; Multiple Sclerosis; Osteoarthritis; Sjögren's Syndrome; Parkinson's Disease

Summary: maintaining a healthy diet and engaging in routine physical activity may help decrease severity of symptoms, prevent secondary conditions, and slow functional decline in people with disabling neuromusculoskeletal conditions. however, people with these conditions face many health barriers to engaging in healthy behaviors. with the advent of portable technologies, such as smart phones, tablets and pdas, there is a need to explore whether these technologies can help people with disabling conditions to stay motivated and overcome barriers to engaging in healthy behaviors.

the overarching goal of this mixed methods, comparative effectiveness randomized controlled pilot study is to evaluate whether goal setting, self-monitoring, and barrier management using a computer tablet can increase physical activity behavior, improve nutritional habits, and promote health-related quality of life in people with disabling neuromusculoskeletal conditions. our hypothesis is that, in comparison to the standard care contact control group, participants in both the tablet group and the paper and pencil group will yield significant improvements in healthy behaviors,with the tablet group yielding significantly larger increases.

Eligibility criteria:
inclusion criteria: * physician-confirmed diagnosis of a neuro-musculoskeletal condition or disease of the nerves, muscles, and/or bones that results in functional limitations * physician consent to engage in home exercise/physical activity program * regularly inactive (i.e., engaging in 90 minutes or less of purposeful physical activity each week) * scoring ≤17 mental composite and ≤16 physical composite on the global health questionnaire. * have internet access (i.e., home, library or other wifi location) exclusion criteria: * if the only disabling condition reported is not considered a neuro-musculoskeletal disease * have hand-motor function impairments that would limit use of the tablet * often engage in healthy eating habits * are frequent fallers (i.e., more than 3 falls per month) * have a diagnoses of chronic obstructive pulmonary disease, serious mental health disorder, chronic heart failure, myocardial infarction, and other unstable/severe cardiovascular conditions, and uncontrolled diabetes mellitus (e.g., admission to the hospital within the past 6 months for uncontrolled diabetes) * have severe cognitive deficits * reports consistently tracking and monitoring health behaviors * unable to effectively use the tablet technology during the pre-intervention usability demonstration

Keywords: neuromusculoskeletal condition
gemcitabine and oxaliplatin in treating patients with metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. it is not yet known whether giving both of these drugs on the same day is more effective than giving them on different days. purpose: this randomized phase iii trial is studying two different schedules of gemcitabine and oxaliplatin to compare how well they work in treating patients with metastatic pancreatic cancer.

objectives: primary * compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with two different schedules of gemcitabine hydrochloride and oxaliplatin. secondary * compare the clinical benefits and tolerability of these regimens in these patients. * compare the progression-free and overall survival of patients treated with these regimens. outline: this is a randomized, multicenter study. patients are stratified according to the participating center and ecog performance status (0 or 1 vs 2). patients are randomized to 1 of 2 treatment arms. * arm i: patients receive gemcitabine hydrochloride iv over 100 minutes on day 1 and oxaliplatin iv over 2 hours on day 2. * arm ii: patients receive gemcitabine hydrochloride iv over 100 minutes followed by oxaliplatin iv over 2 hours on day 1. in both arms, treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed periodically. projected accrual: a total of 80 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the pancreas * metastatic disease * measurable disease (primary tumor or metastasis) * at least 1 cm in diameter by spiral ct scan * no ampulla of vater carcinoma or biliary adenocarcinoma * no known brain metastases patient characteristics: * ecog performance status (ps) 0-2 or karnofsky ps 60-100% * life expectancy more than 12 weeks * absolute neutrophil count \> 1,500/mm\^3 * platelet count \> 100,000/mm\^3 * alkaline phosphatase \< 5 times normal * bilirubin \< 1.5 times normal * creatinine \< 1.5 times normal * no pre-existing neuropathy * no unstable or uncontrolled pain * not pregnant or nursing * fertile patients must use effective contraception * no serious cardiovascular disease * no serious respiratory disease * no uncontrolled or persistent hypercalcemia * no psychological, familial, social, or geographical condition that would preclude study treatment * no other active malignancy prior concurrent therapy: * no prior chemotherapy or radiotherapy * no concurrent corticosteroids

Keywords: adenocarcinoma of the pancreas stage iv pancreatic cancer
understanding decision making processes for undergoing genetic testing among women with newly diagnosed breast cancer

Conditions: Breast Cancer

Summary: genes are the "blueprints" for our bodies. some people are born with an abnormal copy ("mutation") of a gene. these people may have a higher chance of getting a disease. different mutations in different genes cause different diseases. some women get breast cancer because they are born with an abnormal copy of a gene called brca1 or brca2. these women also have a higher chance of getting ovary cancer. women with breast cancer and an abnormal copy of brca1 or brca2 also have a higher chance of getting a second breast cancer in their other breast. because of this, women who might have a mutation may have genetic testing soon after their breast cancer diagnosis to learn about their risks of getting another cancer. genetic testing may be done right after a woman has been diagnosed with breast cancer. it may also be done later, after surgery is done to treat the cancer. the investigators do not know when it is best to do genetic testing. the investigators are doing this study to try to understand whether women prefer testing before or after surgery. the investigator also want to find out how they feel about their choice later on, when their diagnosis in more in their past.


Eligibility criteria:
inclusion criteria: * diagnosis of invasive breast cancer or dcis * appropriate for genetic testing, defined as if they meeting one or more of the following criteria (note that patients may be appropriate for genetic testing even if they do not meet these criteria, but nccn and most payers recognize these groups as clearly appropriate for testing) * must be a primary malignancy (not recurrence), but can be second diagnosis if is a contralateral cancer and the first cancer was not treated with mastectomy * female age ≥18, * if ashkenazi jewish: breast cancer diagnosis ≤ 60. subjects will be presumed to be of ashkenazi ethnicity if jewish religious preference is confirmed in subject and at least 1 parent, unless they explicitly endorse sephardic, iranian, yemeni/ethiopian, or bukharan jewish decent, in which case non-ashkenazi criteria will be applied. if not ashkenazi jewish: * breast cancer diagnosis ≤ 45 or * bilateral breast cancer, with first diagnosed ≤ 50 or * breast cancer diagnosed at any age with a male relative with breast cancer or * breast cancer diagnosis ≤ 50 with one or more of the following:: * 1 or more relative with breast cancer ≤ 50 or * 1 or more relative with ovarian cancer * have not completed definitive surgical treatment * for patients planning mastectomy for treatment, has not yet undergone mastectomy * for patients planning breast conservation for treatment, has not yet begun adjuvant radiation therapy exclusion criteria: * lcis without invasive cancer (idc or ilc) and without dcis * previous breast cancer treated with mastectomy * plan for neoadjuvant chemotherapy before surgery * unable to complete english language questionnaires, as instruments have not been validated in non-english speaking populations

Keywords: genetic testing brca testing ashkenazi descent 11-086
a comparative study of the efficacy of multimodal interventions for tenosynovitis

Conditions: TGCT

Summary: the goal of this clinical trial is to compare the efficacy of four treatments in patients with hand tenosynovitis. the main questions it aims to answer are: which treatment most effectively reduces pain and improves joint function? how do the treatments differ in improving strength and range of motion? researchers will compare four groups-basic manipulation, tui na manipulation, blood flow restriction (bfr) training, and magnetic bead application combined with tui na-to see if there are differences in clinical outcomes. participants will: be randomly assigned to one of the four treatment groups. receive interventions twice a week for 4-8 weeks. undergo assessments of pain, function, range of motion, and strength before, during, and after the treatment period.


Eligibility criteria:
inclusion criteria: * 18 to 60 years of age. * case diagnosis reporting symptoms of tenosynovitis of the hand for at least 3 months. * constant-murley shoulder score: score less than or equal to 60. * dysfunction of the upper extremity, shoulder, and hand scale (dash scale): dash score less than 40. * mayo wrist score: score less than or equal to 60. * positive test results on 2 or more scales during pre-test screening. * no structural lesions or congenital malformations of the hand or wrist. * finkelstein's test: positive (pain occurs when patient holds thumb and bends wrist toward little finger). * fist clenching test: positive (pain increases when patient clenches fist and attempts to bend wrist toward little finger). * no prior hand or wrist surgery or external injuries. * no serious cardiac, pulmonary, neurological, or other systemic diseases. * sufficient exercise capacity to complete exercise loads of required intensity and duration. exclusion criteria: * not between 18 and 60 years of age. * failed wrist function screening. * failed special tests. * presence of structural wrist lesions or congenital wrist deformities. * history of wrist surgery, significant trauma, or wounds. * problems with skin irritation, infections, or open wounds. * conditions like anemia or low blood pressure. * serious cardiac, pulmonary, neurological, or other systemic diseases. * inability to cooperate with trial requirements or refusal to participate.
pediatric switch study for children and adolescent patients with epilepsy

Conditions: Pediatric Epilepsy

Summary: to assess the tolerability of switching from depakote sprinkle capsules or depakote tablets to depakote er tablets in the pediatric population.


Eligibility criteria:
inclusion criteria: * male or female patient with a clinical diagnosis of epilepsy considered stable by the investigator. * must be in good physical health, on the same dose of all medications, including depakote and other aeds, for 2 week period prior to randomization. * minimum body weight of 37 lbs. exclusion criteria: * six-month history of drug or alcohol abuse. * status epilepticus within 6 months prior to screening. * abnormal platelet or alt/ast levels.
evaluating the efficacy and feasibility of a novel wireless ecg recording system in monitoring patients after atrial fibrillation ablation procedure

Conditions: Persistent Atrial Fibrillation; Paroxysmal Atrial Fibrillation

Summary: the investigators goal in this study is to examine the feasibility and efficacy of alivecor iphone case monitoring device in monitoring patients after af ablation by comparing transmissions using alive cor with transmissions from a traditional transtelephonic monitor (ttm). a secondary goal is to assess the ease of use of alivecor device compared to traditional ttm system from the patient's perspective


Eligibility criteria:
inclusion criteria: 1. male or female between \> 18 and \< 75 years of age 2. paroxysmal or persistent atrial fibrillation 3. scheduled to undergo an af ablation procedure 4. already has iphone 4 or iphone 4s with data plan 5. willing to use the iphone alive cor case 6. written informed consent exclusion criteria: 1. unable or unwilling to use the alive cor case for their iphone or iphone 4s 2. residing outside the united states
prognostic nomogram of extranodal nk/t-cell lymphoma

Conditions: Extranodal NK/T-cell Lymphoma

Summary: this study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in enktl, and establish a prognostic predictive nomogram for enktl patients.

this is a retrospective cohort study using anonymized information from patients with enktl. the following criteria are required: (1) patients diagnosed with enktl between january 1, 2000 and august 31, 2020; (2) patients older than 18 years. the pathology of initial diagnosis was reviewed by designated pathologists.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed with enktl * patients diagnosed between january 1, 2000 and august 31, 2020 * patients older than 18 years exclusion criteria: * patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.